p21 (phospho-T145) polyclonal Antibody | BS4142

p21 (phospho-T145) polyclonal Antibody | BS4142 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: IHC

Application Range: IHC: 1:50~1:200

Background: It is now well established that cyclins play a positive role in promoting cell cycle transitions via their ability to associate with and activate their cognate cyclin-dependent kinases (Cdks) . Cdk2 associates with cyclins A, D and E, and has been implicated in the control of the G1 to S phase transition in mammals. A novel Cdk-interacting protein, designated p21, Cip1 or WAF1, has been identified in cyclin A, cyclin D1, cyclin E and Cdk2 immunoprecipitates. p21 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk 2, cyclin E-Cdk2, cyclin D1-Cdk4 and cyclin D2-Cdk4 complexes. Expression of p21 is inducible by wildtype, but not mutant, p53. The mouse homolog of p21 is designated CAP20.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: p-p21 (T145) polyclonal Antibody detects endogenous levels of p21 protein only when phosphorylated at Thr145

Molecular Weight: ~ 21 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Cyclin-dependent kinase inhibitor 1; CDK-interacting protein 1; Melanoma differentiation-associated protein 6; MDA-6; CDKN1A; CAP20; CDKN1; CIP1; MDA6; PIC1; SDI1; WAF1

Immunogen: Synthetic phosphopeptide derived from human p21 around the phosphorylation site of Threonine 145.

Conjugate: Unconjugated

Modification: Phosphorylation

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: Regulation of Apoptosis,Hypoxia Signaling,Warburg Effect,Signaling Pathways Activating p38 MAP KinaseCell Cycle Control G1 S Checkpoint,Examples of Crosstalk Between Post-translational Modifications,Cell Cycle G2 M DNA Damage Signaling Pathway,